Please use this identifier to cite or link to this item:
|Title:||Engineered antibodies act as targeted therapies in cancer treatment.|
|Citation:||Mohindru M, Verma A. Engineered antibodies act as targeted therapies in cancer treatment. Indian Journal of Pediatrics. 2005 Nov; 72(11): 943-7|
|Abstract:||Over the last two decades cancer cure rates have not gone up as expected, and the effectiveness of chemotherapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Monoclonal antibodies against cancer cells offer targeted therapies with little or no toxicities against normal tissues. In this review we will discuss the concepts behind the development of monoclonal antibodies in cancer and their present status in the clinic. Specifically, we will discuss the clinical use of Rituximab (RituxanO), Trastuzumab (HerceptinO) and Bevacizumab (AvastinO) in various cancers and the key clinical trials that have led to their incorporation in cancer therapeutics.|
|Appears in Collections:||Indian Journal of Pediatrics|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.